Bio-Gene Technology Balance Sheet Health
Financial Health criteria checks 4/6
Bio-Gene Technology has a total shareholder equity of A$2.8M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$3.2M and A$368.4K respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | n/a |
| Cash | AU$2.21m |
| Equity | AU$2.79m |
| Total liabilities | AU$368.45k |
| Total assets | AU$3.16m |
Recent financial health updates
We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely
Feb 22
Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Oct 25Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Jun 20Recent updates
We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely
Feb 22Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Oct 25Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Jun 20Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future
Apr 28What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation
Jan 11Financial Position Analysis
Short Term Liabilities: BGT's short term assets (A$2.9M) exceed its short term liabilities (A$345.9K).
Long Term Liabilities: BGT's short term assets (A$2.9M) exceed its long term liabilities (A$22.5K).
Debt to Equity History and Analysis
Debt Level: BGT is debt free.
Reducing Debt: BGT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGT has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BGT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.5% each year